Alnylam pharmaceuticals reports fourth quarter and full year 2022 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended december 31, 2022 and reviewed recent business highlights. “2022 was another year of strong progress at alnylam, including our continued commercial execution which delivered 35% full-year product revenue growth (43% with constant exchange rate*) compared to 2021.
ALNY Ratings Summary
ALNY Quant Ranking